Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Ana Pejčić, Slobodan M. Janković, Miralem Đešević, Refet Gojak, Snežana Lukić, Nenad Marković & Miloš Milosavljević. (2021) Novel and emerging therapeutics for genetic epilepsies. Expert Review of Neurotherapeutics 21:11, pages 1283-1301.
Read now
Read now
Lianmei Wang, Jingzhuo Tian, Suyan Liu, Yanyan Zhang, Jing Liu, Yan Yi, Chunying Li, Yong Zhao, Yushi Zhang, Jiayin Han, Chen Pan, Guiqin Li, Zhong Xian & Aihua Liang. (2020) Shuxuening injection, derived from Ginkgo biloba leaf, induced pseudo-allergic reactions through hyperactivation of mTOR. Pharmaceutical Biology 58:1, pages 581-589.
Read now
Read now
Articles from other publishers (26)
Lily Park, Sophia Reyes-Hadsall, Rummit Dhillon, Alejandra Frauenfelder, Ana Graneiro, Folasade F. Fayiga, Carlos Lange & Ana M. Duarte. (2023) Concerning Newborn Rashes and Developmental Abnormalities: Part II: Congenital Infections, Ichthyosis, Neurocutaneous Disorders, Vascular Malformations, and Midline Lesions. Pediatrics in Review 44:8, pages 447-465.
Crossref
Crossref
Simone Bonazzi, Audrey Gray, Noel M. Thomsen, Jonathan Biag, Nancy Labbe-Giguere, Erin P. Keaney, Hasnain A. Malik, Yingchuan Sun, Jill Nunez, Rajeshri G. Karki, Mark Knapp, Robert Elling, John Fuller, Gwynn Pardee, Lucas Craig, Ketthsy Capre, Sarah Salas, Aakruti Gorde, Guiqing Liang, Danuta Lubicka, Stephanie M. McTighe, Carleton Goold, Shanming Liu, Lin Deng, Jin Hong, Alexander Fekete, Pascal Stadelmann, Wilfried Frieauff, Azeddine Elhajouji, Daniel Bauer, Andreas Lerchner, Branko Radetich, Pascal Furet, Grazia Piizzi, Doug Burdette, Christopher J. Wilson, Stefan Peukert, Lawrence G. Hamann, Leon O. Murphy & Daniel Curtis. (2023) Identification of Brain-Penetrant ATP-Competitive mTOR Inhibitors for CNS Syndromes. Journal of Medicinal Chemistry 66:13, pages 9095-9119.
Crossref
Crossref
Z. G. Tadtaeva, A. N. Galustyan, O. A. Gromova & I. S. Sardaryan. (2023) Third generation antiepileptic drugs: mechanism of action, pharmacokinetics, interaction and use in childhood. Epilepsy and paroxysmal conditions 15:2, pages 160-170.
Crossref
Crossref
Wenqing Chen, Jifa Zhang, Yiwen Zhang, Jiaxian Zhang, Wanling Li, Leihao Sha, Yilin Xia & Lei Chen. (2023) Pharmacological modulation of autophagy for epilepsy therapy: Opportunities and obstacles. Drug Discovery Today 28:6, pages 103600.
Crossref
Crossref
Tingting Hu, Jifa Zhang, Jiaxing Wang, Leihao Sha, Yilin Xia, Tyler C. Ortyl, Xiaohe Tian & Lei Chen. (2023) Advances in Epilepsy: Mechanisms, Clinical Trials, and Drug Therapies. Journal of Medicinal Chemistry 66:7, pages 4434-4467.
Crossref
Crossref
Muh-Lii Liang, Ting-Chi Yeh, Man-Hsu Huang, Pao-Shu Wu, Shih-Pei Wu, Chun-Chao Huang, Tsung-Yu Yen, Wei-Hsin Ting, Jen-Yin Hou, Jia-Yun Huang, Yi-Huei Ding, Jia-Huei Zheng, Hsi-Che Liu, Che-Sheng Ho, Shiu-Jau Chen & Tsung-Han Hsieh. (2023) Application of Drug Testing Platforms in Circulating Tumor Cells and Validation of a Patient-Derived Xenograft Mouse Model in Patient with Primary Intracranial Ependymomas with Extraneural Metastases. Diagnostics 13:7, pages 1232.
Crossref
Crossref
Francis Fagnani, Caroline Laurendeau, Marie de Zelicourt & Jade Marshall. (2022) Epidemiology and disease burden of tuberous sclerosis complex in France: A population‐based study based on national health insurance data. Epilepsia Open 7:4, pages 633-644.
Crossref
Crossref
Karen Litwa. (2022) Shared mechanisms of neural circuit disruption in tuberous sclerosis across lifespan: Bridging neurodevelopmental and neurodegenerative pathology. Frontiers in Genetics 13.
Crossref
Crossref
Alan Talevi. (2022) Antiseizure medication discovery: Recent and future paradigm shifts. Epilepsia Open 7:S1.
Crossref
Crossref
Danelo Estienne du Plessis, Stefan Hofmeyr & Andre van der Merwe. (2022) Clinical Challenge in Urology: Management of a 11-Year-Old Boy With Tuberous Sclerosis Associated Renal Cell Carcinoma. Urology 165, pages e9-e10.
Crossref
Crossref
Humphrey Mapuranga, Bianca Douglas-Jones, Danelo du Plessis, Camilla E. le Roux, Christel du Buisson & Shahida Moosa. (2022) A rare case of tuberous sclerosis complex-associated renal cell carcinoma. South African Journal of Radiology 26:1.
Crossref
Crossref
Lin Wan, Wen He, Yang-Yang Wang, Yong Xu, Qian Lu, Meng-Na Zhang, Qiu-Hong Wang, Shuo Dun, Li-Ying Liu, Xiu-Yu Shi, Jing Wang, Lin-Yan Hu, Bo Zhang, Guang Yang & Li-Ping Zou. (2022) Vigabatrin-associated brain abnormalities on MRI in tuberous sclerosis complex patients with infantile spasms: are they preventable?. Therapeutic Advances in Neurological Disorders 15, pages 175628642211381.
Crossref
Crossref
Maryam Nabavi Nouri, Maria Zak, Puneet Jain & Robyn Whitney. (2022) Epilepsy Management in Tuberous Sclerosis Complex: Existing and Evolving Therapies and Future Considerations. Pediatric Neurology 126, pages 11-19.
Crossref
Crossref
Medo Gutic, Ardea Milidrag, Azra Gutic Cikotic, Milos Danilovic, Teodora Safiye, Ivana Bulatovic, Milos N. Milosavljevic & Slobodan Jankovic. (2021) Rare Neurological Diseases: an Overreview of Pathophysiology, Epidemiology, Clinical Features and Pharmacoeconomic Considerations in the Treating. Serbian Journal of Experimental and Clinical Research 0:0.
Crossref
Crossref
Dominika Miszewska, Monika Sugalska & Sergiusz Jóźwiak. (2021) Risk Factors Associated with Refractory Epilepsy in Patients with Tuberous Sclerosis Complex: A Systematic Review. Journal of Clinical Medicine 10:23, pages 5495.
Crossref
Crossref
Melissa Barker‐Haliski, Kevin Knox, Dannielle Zierath, Zachery Koneval, Cameron Metcalf, Karen S. Wilcox & H. Steve White. (2021) Development of an antiepileptogenesis drug screening platform: Effects of everolimus and phenobarbital. Epilepsia 62:7, pages 1677-1688.
Crossref
Crossref
Laurent M. Willems, Adam Strzelczyk & Felix Rosenow. (2021) Everolimus als krankheitsspezifische Therapieoption bei mit tuberöser Sklerose assoziierter, therapierefraktärer Epilepsie – ein systematischer ÜberblickEverolimus as disease-specific treatment option in tuberous sclerosis complex-associated drug refractory epilepsy—a systematic review. Zeitschrift für Epileptologie 34:2, pages 168-174.
Crossref
Crossref
Chiara Borsari, Erhan Keles, Andrea Treyer, Martina De Pascale, Paul Hebeisen, Matthias Hamburger & Matthias P. Wymann. (2021) Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood–brain barrier permeability. RSC Medicinal Chemistry 12:4, pages 579-583.
Crossref
Crossref
Cecilie Johannessen Landmark, Heidrun Potschka, Stéphane Auvin, Jo M. Wilmshurst, Svein I. Johannessen, Dorothée Kasteleijn‐Nolst Trenité & Elaine C. Wirrell. (2021) The role of new medical treatments for the management of developmental and epileptic encephalopathies: Novel concepts and results. Epilepsia 62:4, pages 857-873.
Crossref
Crossref
Jakob Stockinger, Adam Strzelczyk, Andrea Nemecek, Michal Cicanic, Frank Bösebeck, Christian Brandt, Hajo Hamer, Tassanai Intravooth & Bernhard J. Steinhoff. (2021) Everolimus in adult tuberous sclerosis complex patients with epilepsy: Too late for success? A retrospective study. Epilepsia 62:3, pages 785-794.
Crossref
Crossref
Ruoyu He, Bingyong Xu, Li Ping & Xiaoqing Lv. (2021) Structural optimization towards promising β-methyl-4-acrylamido quinoline derivatives as PI3K/mTOR dual inhibitors for anti-cancer therapy: The in vitro and in vivo biological evaluation. European Journal of Medicinal Chemistry 214, pages 113249.
Crossref
Crossref
Sylvia L. Asa, Stefano La Rosa, Olca Basturk, Volkan Adsay, Marianna Minnetti & Ashley B. Grossman. (2021) Molecular Pathology of Well-Differentiated Gastro-entero-pancreatic Neuroendocrine Tumors. Endocrine Pathology 32:1, pages 169-191.
Crossref
Crossref
Susanne Schubert-Bast & Adam Strzelczyk. (2021) Review of the treatment options for epilepsy in tuberous sclerosis complex: towards precision medicine. Therapeutic Advances in Neurological Disorders 14, pages 175628642110311.
Crossref
Crossref
David M. Ritter & Katherine Holland. (2020) Genetic Testing in Epilepsy. Seminars in Neurology 40:06, pages 730-738.
Crossref
Crossref
Wiebke Theilmann, Birthe Gericke, Alina Schidlitzki, Syed Muhammad Muneeb Anjum, Saskia Borsdorf, Timon Harries, Steven L. Roberds, Dean J. Aguiar, Daniela Brunner, Steven C. Leiser, Dekun Song, Doriano Fabbro, Petra Hillmann, Matthias P. Wymann & Wolfgang Löscher. (2020) Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex. Neuropharmacology 180, pages 108297.
Crossref
Crossref
Chiara Borsari, Erhan Keles, Denise Rageot, Andrea Treyer, Thomas Bohnacker, Lukas Bissegger, Martina De Pascale, Anna Melone, Rohitha Sriramaratnam, Florent Beaufils, Matthias Hamburger, Paul Hebeisen, Wolfgang Löscher, Doriano Fabbro, Petra Hillmann & Matthias P. Wymann. (2020)
4-(Difluoromethyl)-5-(4-((3
R
,5
S
)-3,5-dimethylmorpholino)-6-((
R
)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders
. Journal of Medicinal Chemistry 63:22, pages 13595-13617.
Crossref
Crossref